Rhiza Labs FluTracker Forum

The place to discuss the flu
It is currently Thu Jun 20, 2013 2:09 am

All times are UTC - 5 hours [ DST ]




Post new topic Reply to topic  [ 224 posts ]  Go to page Previous  1 ... 12, 13, 14, 15, 16, 17, 18 ... 23  Next
Author Message
PostPosted: Mon Mar 05, 2012 9:58 am 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
The Anxiety of Influenza

March 12, 2012 .



Related Links Michael Specter: Did a scientist put millions of lives at risk—and was he right to do it?
Keywords Michael Specter; Ron Fouchier; Bird Flu



This week in the magazine, Michael Specter writes about the Dutch scientist Ron Fouchier, who created a virulent strain of bird flu. Here Specter talks with Blake Eskin about Fouchier’s scientific goals, why some critics think his research shouldn’t be published, and why suppressing such research could be more dangerous.


Read more http://www.newyorker.com/online/2012/03 ... z1oFbUI2AJ

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Mon Mar 05, 2012 5:43 pm 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
The scientist
Just how easy is it to make a deadly virus?

This disturbing question has been on the minds of many scientists recently, thanks to a pair of controversial experiments in which the H5N1 bird flu virus was transformed into mutant forms that spread among mammals.

After months of intense worldwide debate, a panel of scientists brought together by the World Health Organization recommended last week in favor of publishing the results. There is no word on exactly when those papers — withheld since last fall by the journals Nature and Science — will appear. But when they do, will it be possible for others to recreate the mutant virus? And if so, who might they be and how would they do it?

Scientists are sharply divided on those questions, as they are on the whole complex of issues surrounding the mutated virus known as mutH5N1.

On the question of who, while terrorists and cults have long been a concern in biosecurity circles, some scientists also fear that publication may allow curious amateurs to recreate the mutated virus — raising the risk of an accidental release.

Over the past decade, more amateur biologists have started to do genetic experiments of their own. One hub of this so-called D.I.Y. biology movement, the Web site DIYbio.org, now has more than 2,000 members.

“I worry about the garage scientist, about the do-your-own scientist, about the person who just wants to try and see if they can do it,” Michael T. Osterholm of the University of Minnesota said last week at a meeting of biosecurity experts in Washington.

Dr. Arturo Casadevall of the Albert Einstein College of Medicine in New York City, who along with Dr. Osterholm is a member of the scientific advisory board that initially recommended against publishing the papers, agreed. “Mike is right,” he said in a telephone interview. “Humans are very inventive.”

Advocates of D.I.Y. biology say such fears not only are wildly exaggerated, but could interfere with their efforts to educate the public.

“I am really sick and tired of folks waving this particular red flag,” said Ellen D. Jorgensen, a molecular biologist who is president of Genspace, a “community biotechnology lab” in Brooklyn.

There are many ways to make a virus. The simplest and oldest way is to get the viruses do all the work. In the 19th century, doctors produced smallpox vaccines by inoculating cows with cowpox viruses. The viruses replicated in the cows and produced scabs, which were then applied to patients, protecting them from the closely related smallpox virus.

By the turn of the century, scientists had discovered how to isolate a number of other viruses from animals and transfer them to new hosts. And by midcentury scientists were rearing viruses in colonies of cells, which made their study far easier. (Viruses have to infect host cells to reproduce; they cannot replicate on their own.)

More recently, scientists discovered how to make new viruses — or at least new variations on old ones. The biotechnology revolution of the 1970s enabled them to move genes from one virus to another.

Flu vaccines can be made this way. Scientists can move some genes from a dangerous flu strain to a harmless virus that grows quickly in chicken eggs. They inject the engineered viruses into the eggs to let them multiply, then kill the viruses to prepare injectable vaccines.

Scientists have also learned how to tweak individual virus genes. They remove a portion of the gene and then use enzymes to mutate specific sites. Using other enzymes, they paste the altered portion back into the virus’s genes.

Another way to make altered viruses is to harness evolution. In a method called serial passage, scientists infect an animal with viruses. The descendants of those viruses mutate inside the animal, and some mutations allow certain viruses to multiply faster than others. The scientists then take a sample of the viruses and infect another animal.

Viruses can change in important ways during this process. If it is done in the presence of antiviral drugs, scientists can observe how viruses evolve resistance. And viruses can become weak, making them useful as vaccines.

At the biosecurity meeting in Washington last week, Ron Fouchier, who led the Dutch team that created one of the mutant H5N1 viruses, described part of the experiments used well-established methods: First they introduced a few mutations into the H5N1 flu genes that they thought might help the bird flu infect mammals. They administered the viruses to the throats of ferrets, waited for the animals to get sick and then transferred viruses to other ferrets. After several rounds, they ended up with a strain that could spread on its own from one ferret to another in the air.



Related

Genetically Altered Bird Flu Virus Not as Dangerous as Believed, Its Maker Asserts (March 1, 2012)


Despite Safety Worries, Work on Deadly Flu to Be Released (February 18, 2012)


How Hard Would It Be for Avian Flu to Spread? (January 3, 2012)


Scientists to Pause Research on Deadly Strain of Bird Flu (January 21, 2012)



If trained virologists could see the full details of the paper, there would be several ways they could make mutH5N1 for themselves. The most sophisticated way would be to make the viruses from scratch. They could take the publicly available genome sequence of H5N1 and rewrite it to include the new mutations, then simply copy the new sequence into an e-mail.

“It’s outsourced to companies that do this for a living,” said Steffen Mueller, a virologist at Stony Brook University on Long Island, who regularly synthesizes flu viruses to design new vaccines.

A DNA-synthesis company would then send back harmless segments of the flu’s genes, pasted into the DNA of bacteria. The scientists could cut out the viral segments from the bacteria, paste them together and inject the reconstructed virus genes into cells. If everything went right, the cells would start making mutH5N1 viruses.

The synthesis companies are on the lookout for matches between requested DNA and the genomes of dangerous pathogens. But some experts say such safeguards are hardly airtight. “You could imagine a determined actor could cleverly disguise orders,” Dr. Casadevall said. “I have a lot of respect for human ingenuity.”

Synthesizing viruses has a high-tech glamour about it, but trained virologists could use a simpler method. Knowing the mutations acquired by mutH5N1, they could simply alter ordinary H5N1 viruses at the same sites in its genes to match it.

Virologists might even be able to figure out how to make mutH5N1 from the few details that have already emerged. According to reports, there were only five mutations in the Dutch viruses, and these were most likely at key sites involved in getting viruses into host cells.

Matthew B. Frieman, a virologist at the University of Maryland School of Medicine, said that a review of the scientific literature could point to where the mutations were inserted. “It’s not like nuclear fission,” he said.

Some of the equipment that scientists use to work on viruses has grown so inexpensive that it is no longer limited to university labs. Devices for duplicating pieces of DNA sell for a few hundred dollars on eBay, for example.

Those falling costs have spurred the rise of the D.I.Y. biology movement; they have also generated concerns about what a do-it-yourselfer might be able accomplish.

D.I.Y. biologists sometimes laugh at the sinister powers people think they have. “People overestimate our technological abilities and underestimate our ethics,” said Jason Bobe, a founder of DIYbio.org.

Todd Kuiken, a senior research associate at the Woodrow Wilson Center in Washington who specializes in the movement, points out that typical D.I.Y. projects are relatively simple, like inserting a gene into bacteria to make them glow. Producing viruses involves much more expensive equipment to do things like rearing host cells. “It’s not going to happen in someone’s basement,” he said.

Nor do these amateurs have the years of training it takes to grow viruses successfully. “It’s like I say, ‘I want to be a four-star chef,’ ” said Dr. Jorgensen, the president of Genspace, who worked with viruses for her Ph.D. “You can read about it, but unless someone teaches you side by side, I don’t think you’re going to get far.”

It is hard to predict how the future evolution of biotechnology will affect the risk of homegrown pathogens.

“There ought to be oversight down the road,” Mr. Bobe said. But he and others question whether holding back scientific information can reduce the risk. While it might be challenging to make one particular flu virus, like mutH5N1, it is not hard to try to breed new flu viruses.

“If you are a farmer somewhere in China, you could do it,” said Dr. Mueller, the virologist at Stony Brook. All that would be necessary is to bring some sick chickens in contact with ferrets or other mammals. “Without knowing what you’re doing, you could do it anyway.”

Of course, someone trying to make a new flu this way might well end up its first victim.

And some experts say that regardless of how a lethal virus might arise, the important thing is to be able to defeat it when it appears, so that we can avoid a global catastrophe like the 1918 flu pandemic, which killed 50 million people.

“The only thing that can be done, and to my mind should be done,” said Ron Atlas, a University of Louisville microbiologist and expert on bioterrorism, “is to have a vaccine that protect against this. We need an urgent program for a generalized influenza vaccine. We would take off the table another 1918-type event.”
http://www.nytimes.com/2012/03/06/healt ... ss&emc=rss

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Mon Mar 05, 2012 6:41 pm 
Offline
User avatar

Joined: Thu Aug 20, 2009 12:28 pm
Posts: 754
Therein lies the dilemma. What Pharmaceutical company is going to invest billions to make large quantities of vaccine (with a shelf life) for a Pandemic that hasn't happened?

And if the responses on THIS website are any indication of Mob mentality, that particular company will be the Big Pharma Bad guy should nature produce this virus on her own accord. THEY will be the ones who stand to gain the "most", and would have to prove their innocence after the initial Holocaust. Even if they made the life saving vaccine... they'd be blamed for the release of the virus. You KNOW they would.

So I don't see a world-wide vaccine program going into effect. Even if they wanted to vaccinate the world "Just in case". The very LOUD anti-vaccine/zombie apocalypse fearing mass public would be in an uproar.
The company could do a huge humanitarian thing, and still be labled the enemy by today's internet pot stiring conspiracy experts.

We've posted the fate of our kind, right into nature's web.

_________________
"Old Mother Goose, when she wanted to wander, would ride through the air on a very fine gander."
1916
"Mother Goose had a house,
'Twas built in a wood,
Where an owl at the door
For sentinel stood."


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 9:23 am 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Future work on lab-made bird flu viruses should be done in most secure labs
By Helen Branswell, The Canadian Press | Associated Press
TORONTO - Future work on mutated bird flu viruses should only take place in laboratories with the highest level of biosafety, suggests a new commentary on the controversy over two studies that led to the creation of these viruses.

But an opposing view argues that to restrict work on the viruses to so-called BSL4 labs would not leave the world safer, but would impede the quest to find out how flu viruses that normally infect birds can adapt to infect people.

The point-counterpoint pieces are published Tuesday in mBio, a journal of the American Society for Microbiology.

The two studies, by Dutch and American researchers, are at the heart of an unprecedented controversy in life sciences. The unpublished works, conducted independently of one another, report on how H5N1 flu viruses can be pushed to become transmissible by aerosols — the equivalent of coughing and sneezing — in ferrets. Ferrets are considered the best animal model for predicting how flu viruses will behave in humans.

The two teams of scientists are eager to publish their work, saying those doing surveillance on H5N1 viruses in places where the viruses spread in poultry and wild birds need to know the combination of mutations that can transform the virus from one that doesn't spread from mammal to mammal to one that can.

But a group of experts that advises the U.S. government on issues of biosecurity deemed the work too dangerous to publish in full, saying the risks of putting the information into the public domain outweigh any benefits the work might garner. The editor-in-chief of mBio, Arturo Casadevall, is a member of that group, the U.S. National Science Advisory Board for Biosecurity.

The dispute over publication has been going on for months. But as it lingers, attention is starting to shift to what should be done with the viruses the Dutch and American teams created. Should additional work on them be allowed? If yes, under what laboratory conditions? Should the source labs be allowed to share the viruses with other researchers in a bid to speed up the acquisition of new knowledge?

The commentaries in mBio don't address all of those questions. But they do weigh in on the conditions under which future work on the viruses should be done.

Adolfo Garcia-Sastre, an influenza microbiologist and co-director for the Emerging Pathogens Institute at New York's Mount Sinai School of Medicine, argues work like this can help scientists evaluate the risks non-human flu strains pose to people.

Little is known, he says, about what makes a flu virus able to transmit effectively in one species but not another. In particular, he says, more research is needed to assess the risk H5N1 viruses pose to humans.

Garcia-Sastre argues that the safety mechanisms and procedures used in BSL3-enhanced laboratories — the type of lab the American and Dutch teams used to create their viruses — offers sufficient protection against a possible escape of the viruses.

"As scientists, we have the responsibility to avoid the undue restrictions of the highest level of biocontainment if enhanced BSL3 facilities can provide the appropriate biosafety."

"The use of BSL4 containment would not decrease the risk of virus release any more than enhanced BSL3 containment, but it would result in an unnecessary burden that would restrict research on H5N1 influenza transmission to a few facilities and considerably decrease the speed of research on this important pathogen," he says.

What Garcia-Sastre doesn't say is that neither the American team, from the University of Wisconsin-Madison, nor the Dutch team, from Erasmus Medical Centre in Rotterdam, has a BSL4 laboratory. In fact, few influenza researchers anywhere would have ready access to BSL4 facilities, which are typically used for study of the most dangerous pathogens such as Ebola virus.

Canada has one BSL4 laboratory, at the National Microbiology Laboratory in Winnipeg. The Public Health Agency of Canada has already determined that if any work is done on the lab-made H5 viruses in this country, it will have to be done in BSL4.

In an editorial he co-wrote to accompany the commentaries, Casadevall notes that one could argue that restricting future work on these viruses to BSL4 labs might make the world more vulnerable to H5N1, because there are few BSL4 labs and the facilities are already in hot demand.

"We know from experience with select agent regulations that as research is made more difficult less work is done," Casadevall and Thomas Shank, chair of the publications board of the American Society of Microbiology say.

But a colleague of Casadevall's from the NSABB says the lab-made viruses must be restricted to BSL4. Michael Imperiale, an NSABB member, and Michael Hanna, both of the University of Michigan at Ann Arbor, argue that in making the H5N1 virus transmissible among mammals the two research teams changed its biosafety profile.

"If a BSL3 worker were to be infected with natural H5N1 virus, the infection would likely stop in that individual," they say. "With human-to-human aerosol transmission" — which the lab-made viruses may be capable of — "others could become infected."

Hanna is the manager of biological and laboratory safety at the university. Imperiale is a professor of microbiology.

They also note BSL4 labs would have greater physical security, lowering the risk someone might breach the facilities and steal samples of the viruses.

"We owe it to the public worldwide to demonstrate that we are working with these viruses in a responsible manner," Imperiale and Hanna argue.

http://news.yahoo.com/future-lab-made-b ... 23846.html

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 9:43 am 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Public release date: 6-Mar-2012
[ Print | E-mail | Share ] [ Close Window ]

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

New H5N1 viruses: How to balance risk of escape with benefits of research?


In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses. The commentaries will be published in mBio®, the online open-access journal of the American Society for Microbiology, on Tuesday, March 6.

This fall, the U.S. National Science Advisory Board for Biosecurity (NSABB) set off a debate when it asked the authors of two recent H5N1 research studies and the scientific journals that planned to publish them to withhold crucial details of the research in the interest of biosecurity. The researchers had taken H5N1, a virus that cannot easily transmit from human to human, and developed strains of the virus that can transmit easily between ferrets, which are a common model for human influenza.

These H5N1 strains and others like them that might be developed in the future could pose a grave threat to human life, but researchers and others argue that studying these H5N1 strains could help bolster preparedness efforts and vaccine development to help fend off a potential H5N1 pandemic. How can we balance the need to protect human life from the accidental escape of an H5N1 strain with the need to continue research that might prevent a naturally occurring outbreak? Which biosafety level (BSL) is right for the H5N1 virus?

In the commentaries appearing in mBio, two experts offer opposing views of the appropriate level of security for dealing with H5N1 viruses. The authors agree that, with a reported case fatality rate that could be as high as 50% or more, H5N1 could create a pandemic of disastrous proportions, but they differ in their opinions of how to strike a balance between biosecurity and potentially life-saving research.

"The existence of mammalian transmissible H5N1 immediately poses the question of whether the current biosafety level of containment is adequate," writes mBio® Editor in Chief Arturo Casadevall in an accompanying editorial. "It is important to understand that the choice of BSL level has profound implications for society."

Under current U.S. guidelines H5N1 is classified as a select agent and must be worked with under BSL-3 with enhancements. The BSL-3 designation is given to pathogens that can be transmitted through the air and can cause serious or fatal disease but for which treatment exists. Most facilities in the United States with infectious disease research programs have BSL-3 laboratories. In addition, many hospitals have areas that can be operated at this level; these areas are used for isolating patients with highly contagious diseases. In contrast, BSL-4 is reserved for pathogens for which there is no known treatment and BSL-4 laboratory requirements are such that there are only four working BSL-4 laboratories in the United States.

Adolfo García-Sastre of the Mount Sinai School of Medicine argues that the H5N1 viruses in question may well be less pathogenic than they were before passage through ferrets, but they could still be quite dangerous, so preventing human exposure is crucial. However, he says, the ultimate level of biosecurity, BSL-4, is excessive in this case and would stifle the pace of discovery. There are both therapeutics and vaccines available for H5N1, says García-Sastre, so he advocates for conducting the research in enhanced BSL-3 facilities, which he says offer the necessary security measures, including interlocked rooms with negative pressure, HEPA-filtered air circulation, and appropriate decontamination and/or sterilization practices for material leaving the facility.

Michael Imperiale and Michael Hanna of the University of Michigan, on the other hand, make their case that the H5N1 viruses merit BSL-4 containment. Although H5N1 that cannot be transmitted from human to human would normally be handled in a BSL-3 facility, researchers changed the virus' biosafety profile when they enhanced its ability to transmit between mammals. According to Imperiale and Hanna, the vaccine for H5N1 is not widely available, and drug resistance and a slow distribution system for antiviral drugs mean a small outbreak could never be contained.

Since the controversy began in December, H5N1 viruses and flu research continue to be the source of much debate. mBio® and the American Society for Microbiology present these commentaries as a means of fostering a discussion and eventually achieving consensus about H5N1 biosecurity that is based on the scientific facts surrounding the subject.

###

PLEASE NOTE: The articles will be available to the general public on the mBio® website after 10:00 a.m. on March 6, 2012.

mBio® is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org.

The American Society for Microbiology is the largest single life science society, composed of over 39,000 scientists and health professionals. ASM's mission is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide.
http://www.eurekalert.org/pub_releases/ ... 030112.php

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 9:56 am 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Current and future BSL4 labs in US
http://www.upmc-biosecurity.org/website ... able1.html

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 2:04 pm 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Since the US government asked the National Science Advisory Board for Biosecurity (NSABB) last week to reconsider revised manuscripts of controversial H5N1 research, which contain “new” and “clarified older data” not evaluated previously by the NSABB, several members of the security board, as well as a senior US congressman, have spoken out about the unfolding events.

Lynn Enquist, molecular biologist at Princeton University and one of the 23 voting members of the NSABB panel told ScienceInsider that the H5N1 experiments carried out independently by research teams at Erasmus Medical Center in Rotterdam, the Netherlands, and the University of Wisconsin, Madison, clearly fall under the classification of “experiments of concern” delineated by the highly influential 2003 National Academies report on biotechnology and terrorism.

“They not only changed the host range of a dangerous pathogen, they also changed its mode of transmission,” she said. “All the other differences in methods, or new or clarified work on virulence in ferrets, does nothing to change those facts.”

Arturo Casadevall, chair of the Division of Infectious Diseases at Albert Einstein College of Medicine told ScienceInsider that while he will go the next NSABB meeting, which is currently scheduled for the end of March, “with an open mind,” he urges caution. “We’re dealing with an organism that we know can cause pandemics and can kill a lot of people.”

Meanwhile, the day after NSABB’s reconsideration of the publication of the H5N1 research, Republican Congressman Jim Sensenbrenner, who is currently vice chair of the House Committee on Science, Space, and Technology, sent a letter to White House science adviser John Holdren saying the Administration’s response to the controversy appears “ad hoc, delayed, and inadequate.”

“The outstanding question is less about why the NSABB is recommending against publication than it is about why this research was performed at all,” he wrote.

The letter also includes a list of questions to Holdren about the mechanisms currently in place to identify, evaluate, and disseminate so-called “dual use research.”
http://the-scientist.com/2012/03/06/h5n ... speak-out/

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 4:07 pm 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Skip to main page content
Home Current Issue Archives Alerts About ASM Contact us Tech Support Journals. ASM .org
Keywords GO
Advanced »

Expand+mBiombio.asm.org
doi: 10.1128/​mBio.00005-12
31 January 2012 mBio vol. 3 no. 1 e00005-12
Mammalian-Transmissible H5N1 Influenza: the Dilemma of Dual-Use Research
Robert G. Webster
+ Author Affiliations

Division of Virology, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
Address correspondence to robert.webster@stjude.org.
Next SectionABSTRACT
The National Science Advisory Board for Biosecurity (NSABB)’s recommendation to restrict publication of the details of the generation of mammalian-transmissible H5N1 influenza virus is unprecedented. Dual-use considerations indicated that the potential biosecurity risks of a transmissible H5N1 virus with a possible mortality of 50% in humans outweigh the substantial benefits of open and complete scientific exchange in this case, although the benefits include potential early detection strategies for H5N1 viruses with specific genetic markers and control strategies, including development of antivirals and vaccines. It is argued that both the funding agency (the National Institute of Allergy and Infectious Diseases) and the scientists were responding to societal needs and acted entirely responsibly. These studies usher in a new era for life sciences, compelling the research community to confront important decisions: under what conditions should such research be done? How can the principle of full release of information be balanced with the moral imperative to protect the public health?

Previous SectionNext SectionCommentary
The majority of biological scientists are surprisingly unaware of dual-use research and the role of the U.S. National Science Advisory Board for Biosecurity (NSABB), although influenza researchers did know that a review board had recommended publication of Jeffrey Taubenberger’s complete sequence of the 1918 Spanish influenza virus (1, 2), despite potential biosecurity risks. Consequently, authors and journals alike were surprised by the NSABB’s recommendation that the full details of the generation of mammalian-transmissible H5N1 influenza virus be withheld. Why the apparent reversal in policy? Why does the risk of publishing the details of H5N1 transmissibility in mammals outweigh the benefits of disseminating important new information of immense human and veterinary public health importance?

The reasons include the greater lethality of H5N1 influenza (>50%) than of Spanish influenza (2.5%) in humans, the availability of highly pathogenic H5N1 viruses in nature, and the nearly universal susceptibility of humans to H5N1 infection. This combination of factors creates an unacceptably high level of risk to humanity should mammalian-transmissible H5N1 virus be accidentally or intentionally released. To cope with this dilemma, the NSABB recommended publication of revised manuscripts that withheld some of the details. A full manuscript would be prepared for distribution to global health officials on a need-to-know basis after further consideration and planning.

Both the Fouchier and Kawaoka groups used the ferret model to demonstrate mammalian transmissibility of highly pathogenic H5N1 virus. While the ferret is considered the best available model of human influenza virus infection and transmission, we do not know whether the ferret fully recapitulates these events in humans. For one thing, H5N1 infection tends to be milder in ferrets than in humans; only a minority of H5N1 strains are lethal in ferrets, whereas lethality greater than 50% has been documented in humans. Thus, while we cannot confidently equate transmissibility and pathogenicity of influenza virus in ferrets and humans, can we afford to disregard data from the best available model?

Concern has been expressed that the agency funding the research (the National Institute of Allergy and Infectious Diseases [NIAID]) and the two groups of scientists conducting the research on H5N1 influenza transmissibility may have acted irresponsibly (3). However, after the 1997 emergence of H5N1 influenza in humans, with its greater than 50% lethality and its potential transmissibility from avians to humans, both the World Health Organization (WHO) (4) and a Blue Ribbon Panel of influenza research advisers to NIAID asserted that further H5N1 research was necessary (5). One of the research recommendations of the 2009 WHO Public Health Research Agenda for Influenza was to “Investigate virus-specific factors associated with zoonotic and pandemic potential (e.g., infectivity, transmissibility, and pathogenicity).” In 2006, the Blue Ribbon Panel on Influenza Research recommended to NIAID that “Learning more about how influenza viruses circulate between animal reservoirs and about the evolutionary pressures that lead to the emergence and spread of new viral subtypes—especially the factors that favor transmission from animals to humans—are urgent research priorities.” Unfortunately, neither the Blue Ribbon Panel nor WHO addressed the question of dual-use research. The focus was on the benefits of knowledge, including the development of better control strategies, such as novel antivirals and vaccines. Now that researchers have generated mammalian-transmissible H5N1 and the U.S. NSABB has raised the dual-use concern, there is a clear and acknowledged need for full discussion of the way forward. WHO has also raised considerable concern about the risk of developing mammalian-transmissible H5N1 viruses.

The two manuscripts formally demonstrating generation of mammalian-transmissible H5N1 influenza virus make major contributions to our knowledge and usher in a new era in the life sciences. The question before the scientific community is how to preserve scientific openness while minimizing risk to the public. Control strategies for influenza and other emerging diseases are not adequately developed; the Fineberg Report on the evaluation of WHO’s response to the 2009 H1N1 pandemic (6) emphasized that “the world is ill prepared to respond to a severe influenza pandemic or to any similarly global, sustained and threatening public health emergency.” The urgent need for general guidance in this matter is reminiscent of the dilemma addressed at the Asilomar conference on recombinant DNA molecules in 1975 (7). One possibility is to involve the national academies of science from all interested countries and WHO in considering the topic of dual-use research and an approach that both promotes research and maintains biosecurity. It has been argued that suppression of information serves no purpose, as the information will inevitably be “leaked.” Although this viewpoint is likely correct, I do not believe we should publish the detailed methods of preparing transmissible H5N1.

Further, we must consider and establish the biosecurity level needed for future work on transmissible H5N1. Because highly pathogenic H5N1 is enzootic in multiple regions of Eurasia, the use of biosecurity level 4 (BSL4) for all H5N1 research would markedly restrict advancement of knowledge needed for vaccine and antiviral research. Enhancing BSL3 biosecurity with electronic surveillance, advanced personal protective equipment (PPE), and prior dual-use assessment of proposed studies is a possibility for further consideration. It is noteworthy that in the United States there were 395 biosecurity breaches involving select agents and 7 laboratory-acquired infections during 2003 to 2009 (8). These incidents, which occurred in both BL3 and BL4 laboratories, highlight the potential risks and the need to fully consider improved biosecurity and the immunization of staff with regularly updated H5N1 vaccines.

The groundbreaking manuscripts by the Fouchier and Kawaoka groups will be of great interest to life scientists and will no doubt increase their familiarity with the concept of dual-use research. These two reports challenge us to take action to ensure that research and open dissemination of knowledge can be safeguarded without compromising biosecurity. Both causes are fundamentally important, but public safety must not be compromised. While bioterrorism is of real concern, nature has the potential to do much greater damage.

Previous SectionNext SectionACKNOWLEDGMENTS
Robert Webster is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, contract no. HSN266200700005C, and by the American Lebanese Syrian Associated Charities.

I thank Sharon Naron for scientific editing and James Knowles for manuscript preparation.

Previous SectionNext SectionNotes
The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM.

Previous SectionNext SectionFootnotes
Citation Webster RG. 2012. Mammalian-transmissible H5N1 influenza: the dilemma of dual-use research. mBio 3(1):e00005-12. doi:10.1128/mBio.00005-12.
Copyright © 2012 Webster.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Previous Section REFERENCES
1.↵ Tumpey TM, et al. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77–88.Abstract/FREE Full Text2.↵ Taubenberger JK, et al. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature 437:889–893.CrossRefMedline3.↵ Enserink M, et al. 2011. Controversial studies give a deadly flu virus wings. Science 334:1192–1193.Abstract/FREE Full Text4.↵ World Health Organization. 2009. WHO Public Health Research Agenda for Influenza, version 1, 2009. http://www.who.int/influenza/resources/ ... _01_en.pdf. Accessed 10 January 2012.
5.↵ NSAID. 2006. Report of the Blue Ribbon Panel on Influenza Research, September 11-12, 2006. http://www.niaid.nih.gov/topics/Flu/Doc ... el2006.pdf. Accessed 10 January 2012.
6.↵ World Health Organization. 2011. Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009 (“Fineberg Report”). http://apps.who.int/gb/ebwha/pdf_files/ ... _10-en.pdf. Accessed 10 January 2012.
7.↵ Berg P, Baltimore D, Brenner S, Roblin RO III, Singer MF. 1975. Asilomar conference on recombinant DNA molecules. Science 188:991–994. FREE Full Text8.↵ Butler D. 2011. Fears grow over lab-bred flu. Nature 480:421–422.M
http://mbio.asm.org/content/3/1/e00005-12.fulledline

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 4:10 pm 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
Science Should Be in the Public Domain
Vincent R. Racaniello
+ Author Affiliations

Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York, USA
Address correspondence to Vincent R. Racaniello, vrr1@columbia.edu.
Next SectionABSTRACT
Variants of avian influenza H5N1 virus that are transmitted by the airborne route among ferrets have been identified. The National Science Advisory Board for Biosecurity has advised against publication of the details of the methods used to obtain these viruses and the amino acid changes that lead to transmission in ferrets. This decision is not based on sound scientific principles and risks setting a precedent that will make it easier to put in place highly restrictive regulations on scientific research and publication.

Previous SectionNext SectionCommentary
Two laboratories recently identified variants of an avian influenza H5N1 virus strain that are transmitted by the airborne route among ferrets (1). When these laboratories submitted their work for publication, the National Science Advisory Board for Biosecurity (NSABB) asked the authors to remove critical details from the manuscripts to ensure that they cannot be used by bioterrorists. This decision is wrong, not only because it rests on weak scientific grounds but also because it threatens to transform the landscape of biological research by setting a precedent to restrict research that can benefit, not harm, humanity.

The goal of the experiments was to determine what makes the influenza H5N1 virus transmissible. This virus strain is lethal in birds, humans, and ferrets, but airborne transmission does not readily occur among humans or ferrets. One group found that after 10 serial ferret-to-ferret passages, a virus that could spread by the aerial route among ferrets was obtained. The NSABB asked that details on how the virus was isolated and the amino acid changes leading to transmissibility be redacted from the manuscript.

A major reason why the NSABB does not want this information made public is that the virus is believed to be highly lethal in humans. The chair of the NSABB notes that he “can’t think of another pathogenic organism that is as scary as this one.” The reason for this view is exemplified by a recent statement about H5N1 in the New York Times: “In its natural form, it is known to have infected only about 600 people since its discovery in 1997, but it killed more than half of them” (2). We cannot say with any certainty that the virus has infected only about 600 people. What we do know is that among the 600 seriously ill individuals infected with H5N1 influenza virus who are admitted to the hospital, over half of them die.

The fatality rate of avian H5N1 influenza virus in humans is determined by dividing the number of fatalities by the number of infections. We do not know the last number—but there are hints that it could be quite large. In a recent study of rural Thai villagers, sera from 800 individuals were collected and analyzed for antibodies against several avian influenza viruses, including H5N1, by hemagglutination inhibition and neutralization assays (3). The results indicate that 73 participants (9.1%) have antibodies against one of two different H5N1 strains, suggesting that subclinical avian influenza virus infections are frequent in Thailand. If 9% of the rural Asian population has been infected with avian H5N1 influenza virus strains, it would dramatically change our view of the pathogenicity of the virus. Extensive serological studies must be done to determine the extent of human infection with avian H5N1 influenza viruses.

Ferrets are not humans and cannot be used to determine whether any influenza virus is a threat to humanity. Ferrets are a good model for influenza—they display similar flu-like symptoms, immune responses, and pathological alterations, such as elevated temperature, weight loss, and histological changes (4). It would be foolish to conclude that ferret influenza is the same as human influenza in all aspects. Not all influenza virus strains have the same virulence in humans and ferrets. An example is the 2009 pandemic H1N1 virus, which caused severe infections in some ferret studies, but was relatively mild in humans (5). The fact that an H5N1 virus is transmissible among ferrets does not mean that it will be equally transmissible among humans. The experiment to answer this question cannot be done.

Passage of viruses in a different host is one strategy for reducing viral virulence in humans. Many live, attenuated viral vaccines have been produced in this way, including vaccines against yellow fever virus and poliovirus (6, 7). The possibility that passage of the H5N1 virus in ferrets will attenuate its virulence in humans has been ignored.

It is highly unlikely that the sequence of the ferret-adapted H5N1 influenza virus would be used for bioterrorism, as its potential for transmission and lethality in humans is unknown. Bioterrorists do not want to carry out an experiment; they want to instill terror. Assuming that the H5N1 virus passaged in ferrets could start a pandemic, knowing the amino acid changes required for transmission in ferrets does not immediately enable construction of a biological weapon. The virus must be recovered from cloned DNA, which requires finely honed skills in virology. A good virologist would have already thought to serially passage the H5N1 virus in ferrets, which would be faster than reconstructing a virus from the nucleotide sequence.

It seems simplistic to assume that laboratory-modified viruses can cause extensive disease in humans. When humans genetically modify viruses, they generally do not know what the virus needs to replicate efficiently, cause disease, and transmit among humans. Consequently, they are likely to introduce changes that attenuate pathogenesis in humans. In nature there is strong selection for fitness and transmission. To think that we can duplicate the enormous diversity and selection pressures that occur in the wild is a severe case of scientific hubris.

No one can guarantee that the ferret-passaged H5N1 virus would not be lethal and transmissible in humans. However, the same could be said about many laboratory-modified viruses, none of which have attracted the attention of the NSABB or the press. When we created the first animal virus from cloned DNA in 1981 (8), there were no calls to redact the paper or prevent further research, despite the theoretical possibility that this reagent might be used to produce more-virulent polioviruses. It was recognized that cloned viral DNA could be used to make important advances in our understanding of viral replication and pathogenesis.

Perhaps more troubling than the weak scientific basis for the NSABB’s argument is the precedent set by withholding experimental details from a scientific publication. Science has always worked best when information is freely accessible. Unexpected individuals from diverse areas often solve difficult research problems. For decades, scientists have carried out experiments on pathogens, and the results have been published in a way that allows other scientists to repeat the experiments, verify conclusions, and expand on what is known. This cycle of publication, replication, and advancement has lead to most scientific and medical advances of the past century and has saved millions of lives. To suggest that studies of legitimate scientific merit should be published without complete methods and data is to abandon a system that brought us to the modern age of medicine.

The decision by the NSABB to restrict publication of data on H5N1 influenza viruses that are transmissible among ferrets is not rooted in sound scientific principles. Of greater concern is that it risks setting a precedent that will make it easier in the future to put in place highly restrictive regulations on scientific research and publication. Fear has clouded the NSABB’s vision. We cannot allow fear to limit our ability to address medical problems.

Previous SectionNext SectionNotes
The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM.

Previous SectionNext SectionFootnotes
Citation Racaniello VR. 2012. Science should be in the public domain. mBio 3(1):e00004-12. doi:10.1128/mBio.00004-12.
Copyright © 2012 Racaniello.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Previous Section REFERENCES
1.↵ Enserink M. 2011. Infectious diseases. Controversial studies give a deadly flu virus wings. Science 334:1192–1193. Abstract/FREE Full Text2.↵ McNeil DG Jr., Grady D. 2 January 2012. How hard would it be for avian flu to spread? New York Times, New York, NY. http://www.nytimes.com/2012/01/03/healt ... wanted=all.
3.↵ Khuntirat BP, et al. 2011. Evidence for subclinical avian influenza virus infections among rural Thai villagers. Clin. Infect. Dis. 53:e107–e116. Abstract/FREE Full Text4.↵ O’Donnell CD, Subbarao K. 2011. The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. Microbes Infect. 13:502–515. Medline5.↵ Itoh Y, et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021–1025.Medline6.↵ Sabin AB, Hennessen WA, Winsser J. 1954. Studies on variants of poliomyelitis virus: I. Experimental segregation and properties of avirulent variants of three immunologic types. J. Exp. Med. 9:551–576.
7.↵ Theiler M. 1930. Susceptibility of white mice to the virus of yellow fever. Science 71:367. FREE Full Text8.↵ Racaniello VR, Baltimore D. 1981. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214:916–919. Abstract/FREE Full Text

http://mbio.asm.org/content/3/1/e00004-12.full

_________________
www.twitter.com/hniman


Top
 Profile  
 
PostPosted: Tue Mar 06, 2012 4:11 pm 
Online

Joined: Wed Aug 19, 2009 10:42 am
Posts: 28252
Location: Pittsburgh, PA USA
The NSABB Recommendations: Rationale, Impact, and Implications
Paul S. Keim
+ Author Affiliations

National Science Advisory Board for Biosecurity, Office of Biotechnology Activities, National Institutes of Health, Bethesda, Maryland, USA; Center for Microbial Genetics and Genomics, Northern Arizona University, Flagstaff, Arizona, USA; and the Translational Genomics Research Institute, Phoenix, Arizona, USA
Address correspondence to paul.keim@nau.edu.
Next SectionABSTRACT
The National Science Advisory Board for Biosecurity (NSABB) has recommended that two scientific papers concerning the laboratory adaptation of avian H5N1 influenza virus to mammal-to-mammal respiratory transmission restrict their content to prevent others from replicating their work. After hearing from experts in the field of influenza research and public health, the benefits of the research were deemed less important than the potential negative consequences. The evaluation followed established NSABB procedures and prior policy recommendations for identifying dual use research of concern (DURC). This recommendation was received by the United States Government, endorsed and forwarded to the research teams and scientific journals involved with the publications.

Previous SectionNext SectionCommentary
In October 2011, the U.S. National Science Advisory Board for Biosecurity (NSABB) was asked to review two papers for their potential as dual-use research of concern (DURC). These papers contained results on the adaptation of the highly pathogenic avian influenza A/H5N1 virus to mammalian hosts such that it could be transmitted via respiratory droplets from animal to animal. We found that this work had great potential for harm or misuse and “recommended that the general conclusions highlighting the novel outcome be published, but that the manuscripts not include the methodological and other details that could enable replication of the experiments by those who would seek to do harm” (NIH Press Release, http://www.nih.gov/news/health/dec2011/od-20.htm). The recommendation “not to publish scientific results” was highly unusual and the first such recommendation by the NSABB membership. We are primarily a group of actively practicing basic research scientists, and we have consistently advocated for open publication practices. As per our advisory nature to the U.S. Government, these recommendations were not binding and could have been ignored. However, after careful consideration, the U.S. Government accepted the recommendations and relayed them to researchers and the scientific journals.

There was agreement by NSABB voting members for these recommendations, though the rationale of individual members as they arrived at the same conclusions varied. We had to judge the beneficial attributes of these research results against their potential to cause harm. Over the last 7 years, NSABB has studied the issues associated with dual-use research, including risk/benefit assessments, and developed principles and tools to guide the deliberative process. Much of this has been formalized in a series of reports and recommendations that are available at a public website (http://oba.od.nih.gov/biosecurity/biosecurity.html). Despite this experience and carefully crafted guidance, there are points in the deliberations where uncertainties and even contradictory information necessitate subjective decisions. When do the negative consequences of research results outweigh the beneficial ones? Is there a clear and bright line to be crossed or is this a more nebulous and fuzzy region of “yes” or “no” for this research? I will present only my personal rationale and how I came to the strong conclusion that this work had the potential to be very dangerous and that its communication should be restricted at this time.

I heard from members of the influenza research community and reviewed the World Health Organization (WHO) data indicating that this avian virus had a very high mortality rate in humans. While the influenza A/H5N1 virus rarely infects humans, when it does it causes catastrophic disease. We are all aware of the rapid global spread of human-adapted influenza both on a yearly basis and during less common pandemics. The documented devastation of the 1918 influenza pandemic, even with its lower mortality rate, was a testament to the powerful potential of influenza. The thought of combining the high human mortality of influenza A/H5N1 with a highly transmissible human-adapted phenotype was sobering. A pandemic by such a pathogen could reasonably be concluded to cause such devastation that it should be prevented at all costs.

I carefully considered how restricting the information would compromise scientific research progress and even how it would hinder public health efforts to prevent such a horrific pandemic. I know from firsthand experience that the free flow of information is part of the best and most productive research endeavors and that any restrictions burden the progress. The conclusion that this virus could be adapted to mammal-to-mammal respiratory transmission was, in my mind, the foremost beneficial part of the research. With this firm conclusion in hand, policy makers, granting agencies, public health officials, and vaccine and drug developers should have both the motivation and a compelling argument to move forward to improve our influenza-fighting infrastructure. The details of the research, on the other hand, would add little to this short-term effort and could enable someone to replicate the work in a short period of time. The short-term negative consequences of restricting experimental details seemed small in contrast to the large consequences of facilitating the replication of these experiments by someone with nefarious intent. Current public health surveillance and public health responses would be enhanced little by these details. This comes not only from my own professional experience in globally tracking dangerous pathogens but also from personally watching the 2009 H1N1 influenza pandemic spread globally. It was impossible to contain, and I believe that the same would be true for an H5N1 influenza pandemic. We were lucky in that the H1N1 virus has low virulence, but the best current data suggest that this would not be the case for the H5N1 virus. Publishing a detailed experimental protocol on how to produce a highly transmissible H5N1 virus in a highly regarded scientific journal is a very bad idea.

Since our recommendations were announced in mid-December, there has been considerable response from scientists, policy makers, funding agencies, and global health organizations. There have been criticisms that we were censoring and compromising academic freedom. There have been criticisms that restriction of the publications was insufficient and that even performing such experiments should be restricted. The debate has touched upon both biosafety and biosecurity aspects, with some calling for the destruction of the virus or for moving all such research to the highest safety level, biosafety level 4 (BSL-4). The NSABB has not yet offered specific recommendations concerning these statements, and my personal opinions are relatively unimportant. What is gratifying and essential is that the debate is occurring; it is occurring on an international stage, and it is occurring rapidly.

In the midst of NSABB deliberations and formulation of our recommendations, the need for a global debate to develop policy has always been in our discussions. Why should the NSABB be telling the world what to do? Why has not the world already had these discussions and debates? How could the NSABB stimulate the process such that global leaders in science, policy, and public health engage in a broad-based conversation on these issues? The specific NSABB recommendations seem to have been accepted and are being implemented by two research groups and two scientific journals; more importantly, the research issue of adapting an avian virus to mammals, potentially humans, is a topic that is being widely discussed. The influenza research community is voluntarily suggesting a moratorium on this type of research. The WHO has agreed to participate and facilitate in policy development. And the U.S. Government is working on guidelines for the distribution of restricted information.

Research and public policy will be developed from this global engagement process, a process that should increase the public’s confidence in the scientific endeavor, in scientists’ ethical behavior, and in the transparency that a free research environment embraces. The NSABB recommendations have been effective in both their primary and secondary goals. They are the right recommendations for this time and this problem.

Previous SectionNext SectionNotes
The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM.

Previous Section Footnotes
Citation Keim PS. 2012. The NSABB recommendations: rationale, impact, and implications. mBio 3(1):e00021-12. doi:10.1128/mBio.00021-12
Copyright © 2012 Keim
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

http://mbio.asm.org/content/3/1/e00021-12.full

_________________
www.twitter.com/hniman


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 224 posts ]  Go to page Previous  1 ... 12, 13, 14, 15, 16, 17, 18 ... 23  Next

All times are UTC - 5 hours [ DST ]


Who is online

Users browsing this forum: niman and 27 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Powered by phpBB® Forum Software © phpBB Group